These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 14645415)

  • 1. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs.
    Arteaga CL
    J Clin Oncol; 2003 Dec; 21(23 Suppl):289s-291s. PubMed ID: 14645415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
    Jänne PA
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies.
    Viloria-Petit AM; Kerbel RS
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):914-26. PubMed ID: 14967451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
    Bianco R; Troiani T; Tortora G; Ciardiello F
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor: a promising target in solid tumours.
    Laskin JJ; Sandler AB
    Cancer Treat Rev; 2004 Feb; 30(1):1-17. PubMed ID: 14766123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy.
    Ang KK; Andratschke NH; Milas L
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):959-65. PubMed ID: 14967456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms and targeting of colorectal cancer.
    Vanhoefer U
    Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
    Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
    Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.
    Krause M; Baumann M
    Cancer Metastasis Rev; 2008 Sep; 27(3):387-402. PubMed ID: 18427731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.
    Arteaga CL; Baselga J
    Clin Cancer Res; 2003 May; 9(5):1579-89. PubMed ID: 12738709
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of novel targeted therapies in the clinic.
    Herbst RS
    Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S21-7. PubMed ID: 15928655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin toxicities of targeted therapies.
    Segaert S; Chiritescu G; Lemmens L; Dumon K; Van Cutsem E; Tejpar S
    Eur J Cancer; 2009 Sep; 45 Suppl 1():295-308. PubMed ID: 19775626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.